Clinuvel Pharmaceuticals (CUV)

Download button icon Download

Clinuvel Pharmaceuticals (CUV): Signals

No data currently available.

data-ad-format="auto">

Explore Compare Share

TECHNICAL ANALYSIS SUMMARY

Clinuvel Pharmaceuticals (CUV.AX)


Indicator:

AVG DIRECTIONAL INDEX


Last Signal:

WEAK TREND


Trading: HOLD @ $17.6
Signal Strength: MEDIUM
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has been constructed to highlight the existence of a trend for an assocaited timeframe. Trend determining indicators can be used in short, medium or long term timeframes & determines if the stock is trending or ranging. Once the trend status is quantified, this can then be coupled to additional indicators to add a significant advantage to the trading strategy.


Clinuvel Pharmaceuticals (ASX:CUV) has confirmed a weak trend is presentClinuvel Pharmaceuticals has an ATR(14) of 1.161, a DX of 5.55 & an ADX(14) of 15.66



The Average Directional Index (ADX) Minus Directional Indicator (-DI) and Plus Directional Indicator (+DI) represent a group of directional movement indicators that form a trading system developed by Welles Wilder.

Calculation: Average Directional Movement Index (ADX):
Trend Strength ;
1) 0-25 = Absent or Weak Trend;
2) 25-50 = Strong Trend;
3) 50-75 = Very Strong Trend;
4) 75-100 Extremely Strong Trend;


PROFILE: Clinuvel Pharmaceuticals (CUV.AX)


Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |

About Clinuvel Pharmaceuticals (ASX:CUV):

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.

Top 10:

Average Directional Index

Download button icon Download
Company Close Change (%) Volume Value Signal
MLD Maca 0.98 12 3,698,813 -24.12 NEUTRAL
BOC Bougainville Copper 0.19 11.8 27,150 18.22 NEUTRAL
APZ Aspen 1 7.5 646,568 19.61 NEUTRAL
ORE Orocobre 5 7.5 2,139,777 21.19 NEUTRAL
ASL Ausdrill 1.53 7.4 3,128,632 -22.1 NEUTRAL
AHY Asaleo Care 0.75 6.4 758,066 14.43 NEUTRAL
CWY Cleanaway Waste Management 1.86 6.3 8,021,245 17.66 NEUTRAL
GTN GTN Resources 2.12 5.5 214,772 14.87 NEUTRAL
VAH Virgin Australia Holdings 0.21 5.1 140,692 13.7 NEUTRAL
ISU Iselect 0.73 4.3 156,675 19.46 NEUTRAL
back to top